SLC1A3 Gene Episodic Ataxia Type 6 NGS Genetic DNA Test
Comprehensive Genetic Testing for Neurological Movement Disorders
The SLC1A3 Gene Episodic Ataxia Type 6 NGS Genetic DNA Test represents a breakthrough in neurological genetic diagnostics, offering precise identification of mutations associated with episodic ataxia type 6. This rare inherited movement disorder affects coordination and balance, with symptoms that typically manifest during childhood or early adulthood. Our advanced testing methodology provides definitive answers for patients and families affected by this challenging condition.
What This Test Measures and Detects
This sophisticated genetic analysis specifically targets the SLC1A3 gene, which encodes the excitatory amino acid transporter 1 (EAAT1) protein. This protein plays a critical role in glutamate transport in the central nervous system. The test identifies:
- Pathogenic variants in the SLC1A3 gene sequence
- Missense, nonsense, and frameshift mutations
- Copy number variations affecting gene function
- Autosomal dominant inheritance patterns
- Specific genetic markers associated with episodic ataxia type 6
Who Should Consider This Genetic Test
This test is particularly recommended for individuals experiencing:
- Recurrent episodes of poor coordination and balance problems
- Involuntary eye movements (nystagmus) during attacks
- Family history of episodic ataxia or movement disorders
- Unexplained neurological symptoms beginning in childhood
- Progressive ataxia with episodic worsening
- Migraine-like symptoms accompanying movement difficulties
- Speech difficulties during neurological episodes
Significant Benefits of Genetic Testing
Undergoing the SLC1A3 genetic test provides numerous advantages:
- Accurate Diagnosis: Confirms or rules out episodic ataxia type 6 definitively
- Personalized Treatment: Enables targeted therapeutic approaches
- Family Planning: Provides crucial information for genetic counseling
- Prognostic Insights: Helps predict disease progression and management
- Early Intervention: Facilitates timely treatment initiation
- Reduced Diagnostic Uncertainty: Eliminates years of diagnostic uncertainty
Understanding Your Test Results
Our comprehensive genetic counseling support helps you interpret your results effectively:
- Positive Result: Indicates the presence of a pathogenic SLC1A3 mutation, confirming episodic ataxia type 6 diagnosis
- Negative Result: Suggests that SLC1A3 mutations are not the cause of symptoms, guiding further diagnostic evaluation
- Variant of Uncertain Significance: Identifies genetic changes requiring additional clinical correlation
- Carrier Status: Provides information about inheritance risk for future generations
Test Pricing Information
| Test Name | Discount Price | Regular Price |
|---|---|---|
| SLC1A3 Gene Episodic Ataxia Type 6 NGS Genetic DNA Test | $500 USD | $700 USD |
Nationwide Testing Availability
We proudly serve patients across the United States with convenient testing locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our comprehensive network ensures accessible genetic testing services for neurological disorders nationwide.
Take Control of Your Neurological Health Today
Don’t let uncertainty about your neurological symptoms continue. Our SLC1A3 genetic test provides the clarity needed for effective treatment planning and peace of mind. With results delivered within 3-4 weeks and comprehensive genetic counseling support, you’ll have the information necessary to make informed healthcare decisions.
Ready to begin your genetic testing journey? Contact our genetic specialists today at +1(267) 388-9828 or book your appointment online. Take the first step toward definitive diagnosis and personalized neurological care.
